Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

Similar articles for PubMed (Select 23557746)

1.

Application of target-mediated drug disposition model to small molecule heat shock protein 90 inhibitors.

Yamazaki S, Shen Z, Jiang Y, Smith BJ, Vicini P.

Drug Metab Dispos. 2013 Jun;41(6):1285-94. doi: 10.1124/dmd.113.051490. Epub 2013 Apr 4.

2.

Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model.

Marathe A, Krzyzanski W, Mager DE.

J Pharmacokinet Pharmacodyn. 2009 Jun;36(3):199-219. doi: 10.1007/s10928-009-9118-8. Epub 2009 May 12.

PMID:
19434483
3.

Dose correction for the Michaelis-Menten approximation of the target-mediated drug disposition model.

Yan X, Krzyzanski W.

J Pharmacokinet Pharmacodyn. 2012 Apr;39(2):141-6. doi: 10.1007/s10928-011-9233-1. Epub 2012 Jan 4.

4.

Target-mediated drug disposition model for drugs that bind to more than one target.

Gibiansky L, Gibiansky E.

J Pharmacokinet Pharmacodyn. 2010 Aug;37(4):323-46. doi: 10.1007/s10928-010-9163-3. Epub 2010 Jul 29.

PMID:
20669044
5.

Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification.

Peletier LA, Gabrielsson J.

J Pharmacokinet Pharmacodyn. 2012 Oct;39(5):429-51. doi: 10.1007/s10928-012-9260-6. Epub 2012 Aug 1.

6.

Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics.

Gibiansky L, Gibiansky E.

Expert Opin Drug Metab Toxicol. 2009 Jul;5(7):803-12. doi: 10.1517/17425250902992901. Review.

PMID:
19505189
7.

Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor.

Yan X, Chen Y, Krzyzanski W.

J Pharmacokinet Pharmacodyn. 2012 Oct;39(5):543-60. doi: 10.1007/s10928-012-9267-z. Epub 2012 Aug 29.

8.
9.

Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models.

Yan X, Mager DE, Krzyzanski W.

J Pharmacokinet Pharmacodyn. 2010 Feb;37(1):25-47. doi: 10.1007/s10928-009-9142-8. Epub 2009 Dec 10.

10.

Target-mediated drug disposition and dynamics.

Mager DE.

Biochem Pharmacol. 2006 Jun 28;72(1):1-10. Epub 2006 Feb 15. Review.

PMID:
16469301
11.

Impact of dose selection on parameter estimation using a rapid binding approximation model of target-mediated drug disposition.

Marathe A, Van Wart S, Mager DE.

J Pharmacokinet Pharmacodyn. 2011 Apr;38(2):223-35. doi: 10.1007/s10928-010-9190-0. Epub 2010 Dec 17.

12.

A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells.

Massey AJ, Williamson DS, Browne H, Murray JB, Dokurno P, Shaw T, Macias AT, Daniels Z, Geoffroy S, Dopson M, Lavan P, Matassova N, Francis GL, Graham CJ, Parsons R, Wang Y, Padfield A, Comer M, Drysdale MJ, Wood M.

Cancer Chemother Pharmacol. 2010 Aug;66(3):535-45. doi: 10.1007/s00280-009-1194-3. Epub 2009 Dec 13.

PMID:
20012863
13.

Approximations of the target-mediated drug disposition model and identifiability of model parameters.

Gibiansky L, Gibiansky E, Kakkar T, Ma P.

J Pharmacokinet Pharmacodyn. 2008 Oct;35(5):573-91. doi: 10.1007/s10928-008-9102-8. Epub 2008 Nov 13.

PMID:
19005743
14.

Dynamics of target-mediated drug disposition.

Peletier LA, Gabrielsson J.

Eur J Pharm Sci. 2009 Dec 8;38(5):445-64. doi: 10.1016/j.ejps.2009.09.007. Epub 2009 Sep 26.

PMID:
19786099
15.

Pre-clinical validation of a novel alpha-7 nicotinic receptor radiotracer, [(3)H]AZ11637326: target localization, biodistribution and ligand occupancy in the rat brain.

Maier DL, Hill G, Ding M, Tuke D, Einstein E, Gurley D, Gordon JC, Bock MJ, Smith JS, Bialecki R, Eisman M, Elmore CS, Werkheiser JL.

Neuropharmacology. 2011 Jul-Aug;61(1-2):161-71. doi: 10.1016/j.neuropharm.2011.03.024. Epub 2011 Apr 7.

PMID:
21497612
16.

Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies.

Cao Y, Jusko WJ.

J Pharmacokinet Pharmacodyn. 2014 Aug;41(4):375-87. doi: 10.1007/s10928-014-9372-2. Epub 2014 Jul 31.

18.

A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors.

Zhou D, Liu Y, Ye J, Ying W, Ogawa LS, Inoue T, Tatsuta N, Wada Y, Koya K, Huang Q, Bates RC, Sonderfan AJ.

Toxicol Appl Pharmacol. 2013 Dec 1;273(2):401-9. doi: 10.1016/j.taap.2013.09.018. Epub 2013 Oct 1.

20.

Preclinical pharmacokinetic analysis of SNX-2112, a novel Hsp90 inhibitor, in rats.

Zhai QQ, Gong GQ, Liu Z, Luo Y, Xia M, Xing GW, You XF, Wang YF.

Biomed Pharmacother. 2011 Mar;65(2):132-6. doi: 10.1016/j.biopha.2010.12.009. Epub 2010 Dec 30.

PMID:
21227627
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk